▲ 2.97%
prev close
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
Congressional Trades
2
All tracked trades
Members Trading
1
Unique members
Net Activity
+2
2 buys · 0 sells
Members Who Traded This Stock
2 trade events
| Date | Member | Stock | Type | Amount | Filed | Signal |
|---|---|---|---|---|---|---|
| 2026-09-29 | ALKSAlkermes plc - Ordinary Shares | Buy | $1,001 - $15,000 | 8d ago | — | |
| 2026-07-30 | ALKSAlkermes plc - Ordinary Shares | Buy | $15,001 - $50,000 | 46d ago | — |
2026-09-29
Gilbert Cisneros
ALKS
Amount
$1,001 - $15,000
Filed
8d ago
2026-07-30
Gilbert Cisneros
ALKS
Amount
$15,001 - $50,000
Filed
46d ago
Recent News
Powered by Polygon.io
HRMY Stock Gains 27.6% in Six Months: Is There More Room for Growth?
4 CNS Drug Stocks Worth Watching This World Mental Health Day
Global Substance Use Disorder Treatment Market Analysis and Forecast to 2030 | Long-Acting Therapies, Telemedicine, and Drug Innovation Drive Growth
Alkermes Posts Positive Data From Phase I ADHD Study on ALKS 7290
Alcohol Use Disorder Market Set to Expand at a 12.1% CAGR During the Forecast Period (2026–2036), Owing to the Emergence of Novel Mechanisms Such as 5-HT3 Pathway, NOP Receptor, mGluR5 NAM, and Other | DelveInsight
Trade Timeline
Congressional activity, newest first
Gilbert Cisneros
2026-09-29 · Purchase
$1,001 - $15,000
Gilbert Cisneros
2026-07-30 · Purchase
$15,001 - $50,000